in this issue
Regions :: North America :: U.S.
Lonza and Sorrento Therapeutics sign research license agreement
9:28 AM MDT | August 7, 2013 | Deepti Ramesh
Lonza and Sorrento Therapeutics (San Diego), a publicly traded, development-stage biopharmaceutical company, say that they have signed a nonexclusive research license agreement for access to Lonza’s GS Xceed Gene Expression System. The GS Xceed System will be used in the generation of stable expression cell lines for the production and development of therapeutic antibodies in Sorrento’s product portfolio. The research license agreement will give Sorrento access to Lonza’s GS technology for use in Sorrento’s maturing pipeline of...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee